TY - JOUR T1 - Adoptive Immunotherapy for Pancreatic Cancer Using MUC1 Peptide-pulsed Dendritic Cells and Activated T Lymphocytes JF - Anticancer Research JO - Anticancer Res SP - 379 LP - 387 VL - 28 IS - 1B AU - HIROSHI KONDO AU - SHOICHI HAZAMA AU - TORU KAWAOKA AU - SHIGEFUMI YOSHINO AU - SHIN YOSHIDA AU - KAZUHISA TOKUNO AU - MOTONARI TAKASHIMA AU - TOMIO UENO AU - YUJI HINODA AU - MASAAKI OKA Y1 - 2008/01/01 UR - http://ar.iiarjournals.org/content/28/1B/379.abstract N2 - Background: Pancreatic cancer has a poor prognosis. The clinical efficacy of immunotherapy using both dendritic cells pulsed with MUC1 peptide (MUC1-DC) and, cytotoxic T lymphocyte (CTL) sensitized with a pancreatic cancer, YPK-1, expressing MUC1 (MUC1-CTL) was evaluated. Patients and Methods: Twenty patients with unresectable or recurrent pancreatic cancer were enrolled. Peripheral blood mononuclear cells (PBMCs) were separated into adherent cells for induction of MUC1-DCs and floating cells for MUC1-CTLs. MUC1-DCs were generated by culture with granulocyte monocyte colony stimulating factor (GM-CSF) and interleukin-4 (IL-4) and then exposed to MUC1 peptide and TNF-α. MUC1-CTLs were induced by co-culture with YPK-1 and then with interleukin-2 (IL-2). MUC1-DCs were injected intradermally and MUC1-CTLs were given intravenously. Results: Patients were treated from 2 to 15 times. One patient with multiple lung metastases experienced a complete response. Five patients had stable disease. The mean survival time was 9.8 months. No grade II-IV toxicity was observed. Conclusion: Adoptive immunotherapy with MUC1-DC and MUC1-CTL may be feasible and effective for pancreatic cancer. ER -